Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
Total Valuation
Bioline RX Ltd Sponsored ADR has a market cap or net worth of $11.32M. The enterprise value is $18.33M.
Market Cap$11.32M
Enterprise Value$18.33M
Share Statistics
Bioline RX Ltd Sponsored ADR has 4,351,358 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,351,358
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bioline RX Ltd Sponsored ADR’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -30.96%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.03
Return on Invested Capital (ROIC)-30.96%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee42.48K
Profits Per Employee-42.30K
Employee Count28
Asset Turnover0.03
Inventory Turnover0.35
Valuation Ratios
The current PE Ratio of Bioline RX Ltd Sponsored ADR is ―. Bioline RX Ltd Sponsored ADR’s PEG ratio is -0.06.
PE Ratio―
PS Ratio9.57
PB Ratio0.63
Price to Fair Value0.63
Price to FCF-1.39
Price to Operating Cash Flow-1.39
PEG Ratio-0.06
Income Statement
In the last 12 months, Bioline RX Ltd Sponsored ADR had revenue of 1.19M and earned -1.18M in profits. Earnings per share was -0.29.
Revenue1.19M
Gross Profit430.39K
Operating Income-10.37M
Pretax Income-2.04M
Net Income-1.18M
EBITDA-9.84M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -8.10M and capital expenditures -25.20K, giving a free cash flow of -8.13M billion.
Operating Cash Flow-8.10M
Free Cash Flow-8.13M
Free Cash Flow per Share-1.87
Dividends & Yields
Bioline RX Ltd Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.11
52-Week Price Change-15.52%
50-Day Moving Average2.62
200-Day Moving Average3.36
Relative Strength Index (RSI)51.29
Average Volume (3m)23.61K
Important Dates
Bioline RX Ltd Sponsored ADR upcoming earnings date is May 27, 2026, Before Open (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateMay 27, 2026
Ex-Dividend Date―
Financial Position
Bioline RX Ltd Sponsored ADR as a current ratio of 1.95, with Debt / Equity ratio of 55.78%
Current Ratio1.95
Quick Ratio1.78
Debt to Market Cap0.81
Net Debt to EBITDA-0.70
Interest Coverage Ratio-8.04
Taxes
In the past 12 months, Bioline RX Ltd Sponsored ADR has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bioline RX Ltd Sponsored ADR EV to EBITDA ratio is -1.86, with an EV/FCF ratio of -2.24.
EV to Sales15.37
EV to EBITDA-1.86
EV to Free Cash Flow-2.24
EV to Operating Cash Flow-2.25
Balance Sheet
Bioline RX Ltd Sponsored ADR has $20.88M in cash and marketable securities with $10.15M in debt, giving a net cash position of $10.73M billion.
Cash & Marketable Securities$20.88M
Total Debt$10.15M
Net Cash$10.73M
Net Cash Per Share$2.46
Tangible Book Value Per Share$1.70
Margins
Gross margin is 75.07%, with operating margin of -871.78%, and net profit margin of -99.58%.
Gross Margin75.07%
Operating Margin-871.78%
Pretax Margin-171.70%
Net Profit Margin-99.58%
EBITDA Margin-827.46%
EBIT Margin-871.78%
Analyst Forecast
The average price target for Bioline RX Ltd Sponsored ADR is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.00
Price Target Upside389.80% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-41.76%
EPS Growth Forecast87.36%